Humaan Albumine Baxalta (Human Serum Albumin)

Humaan Albumine Baxalta is indicated for clinical situations where plasma volume expansion or albumin replacement is required. It is commonly employed in the management of conditions that cause significant fluid loss or low serum albumin concentrations.

• Treatment of hypovolemia associated with acute blood loss, trauma, or dehydration.
• Management of hypoalbuminemia in chronic liver disease, nephrotic syndrome, or malnutrition.
• Volume support for patients undergoing major surgery or extensive burns.
• Adjunct therapy for plasma exchange procedures and extracorporeal circulation.
• Correction of low oncotic pressure in patients with sepsis or critical illness.

• Human serum albumin in Humaan Albumine Baxalta increases plasma oncotic pressure by contributing to the colloid osmotic gradient. The exogenous albumin binds water and various endogenous substances, expanding intravascular volume and improving tissue perfusion. By restoring oncotic balance, it reduces transcapillary fluid shift, supporting hemodynamic stability in patients with low endogenous albumin or fluid loss. It also serves as a carrier for drugs and hormones, influencing their distribution.

Adverse reactions to Humaan Albumine Baxalta are generally infrequent but can range from mild infusion‑related events to rare serious complications.

Common

• Transient fever, chills, or flushing during infusion.
• Mild hypotension or hypertension that resolves after the infusion.
• Headache, nausea, or mild abdominal discomfort.
• Localized swelling or pain at the injection site.

Serious

• Anaphylactic or severe allergic reactions, including rash, bronchospasm, or angioedema.
• Acute circulatory overload leading to pulmonary edema or heart failure.
• Hemolysis or renal impairment associated with contaminated plasma products.
• Thromboembolic events such as deep vein thrombosis or pulmonary embolism.

Monitoring during and after administration helps identify and manage these events promptly.

Clinicians should evaluate patient-specific factors before initiating Humaan Albumine Baxalta to minimize risk and ensure appropriate use.

• Assess baseline serum albumin and fluid status to determine need for volume expansion.
• Use caution in patients with heart failure, renal insufficiency, or pulmonary edema.
• Avoid rapid infusion rates; administer according to recommended guidelines to reduce circulatory overload.
• Monitor vital signs, urine output, and weight during therapy.
• Screen for known hypersensitivity to human albumin or plasma derivatives.
• Consider the risk of infection transmission from plasma-derived products.

Humaan Albumine Baxalta may interact with other therapies that affect fluid balance, coagulation, or immune response, requiring careful coordination.

Avoid

• Avoid using other synthetic colloids such as hydroxyethyl starch or gelatin, as combined therapy raises overload risk.
• Avoid simultaneous nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) in patients with impaired renal function.

Use with caution

• Use diuretics cautiously; albumin may increase intravascular volume, enhancing diuretic‑induced hypotension.
• Use vasopressors cautiously, as albumin‑driven volume expansion can alter required dosing of agents like norepinephrine.
• Use anticoagulants cautiously; changes in plasma volume may affect INR or aPTT results and dosing.
• Use immunosuppressants cautiously, because albumin may modify their distribution and therapeutic monitoring.